Abstract
BackgroundThe use of antimalarial drugs for prevention and treatment is a major strategy in the prevention of malaria in pregnancy. Although sulphadoxine-pyrimethamine (SP) is currently recommended for intermittent preventive treatment of malaria during pregnancy in Nigeria, previously used drugs for prophylaxis such as chloroquine (CQ) and pyrimethamine are accessible as they are purchased over the counter. This study describes the markers of absence or presence of resistance to quinoline (Pfcrt and Pfmdr 1) and type 1 antifolate antimalarial medicines (Pfdhfr).MethodsPlasmodium falciparum-positive dried blood spots from pregnant women attending antenatal clinics for the first time during current pregnancy were investigated for the presence of mutations at codons 72–76 of Plasmodium falciparum chloroquine resistance transporter (Pfcrt) gene by real time polymerase chain reaction (PCR) using haplotype-specific probes. PCR followed by sequence analysis was used to identify mutations at codons 86, 184, 1034, 1042 and 1246 of P. falciparum multi-drug resistance-1 (Pfmdr1) gene; and codons 16, 50, 51, 59, 108, 140 and 164 of Pfdhfr gene.ResultsTwo haplotypes of Pfcrt (n = 54) were observed: CVMNK 13(24.2%) and CVIET 41 (75.9%) of the samples. The SVMNT haplotype was absent in this population. The Pfmdr1 (n = 28) haplotypes were NYSND 15(53.6%), YYSND 5(17.9%), NFSND 6(21.4%) and YFSND 2(7.1%). The Pfdhfr (n = 15) were ACNCSVI 4(26.7%), and ACICNSVI 1(6.7%) and ACIRNVI 10 (66.7%). The rate of occurrence of Pfcrt 76T, Pfdhfr108N, Pfmdr186Yand184F were 75.9%, 73.3%, 25% and 28.1% respectively. The Pfmdr1 86Y was associated with low parasitaemia (median = 71 parasites/μl, P = 0.024) while Pfcrt 76T was associated with young maternal age (mean 24.1 ± 4.5 years; P = 0.006). The median parasitaemia were similar (P>0.05) in wild and mutant strains of Pfcrt 76, Pfmdr1 184 and Pfdhfr 108. There was no association between gravidity or gestational age of the women and presence of mutations in the Pfcrt, Pfmdr1 or Pfdhfr genes (P>0.05).ConclusionMarkers of resistance to chloroquine and pyrimethamine were high, whereas cycloguanil-resistance marker was not present in the studied population. The low level of mutations in the Pfmdr1gene indicates likely efficacy of amodiaquine against malaria in pregnancy.
Highlights
The main strategies for the prevention of malaria during pregnancy in Nigeria are by chemoprophylaxis using sulphadoxine-pyrimethamine (SP) and use of long-lasting insecticide treated nets
This study describes the markers of absence or presence of resistance to quinoline (Pfcrt and Pfmdr 1) and type 1 antifolate antimalarial medicines (Pfdhfr)
The P. falciparum multi-drug resistance-1 (Pfmdr1) 86Y was associated with low parasitaemia while Plasmodium falciparum chloroquine resistance transporter (Pfcrt) 76T was associated with young maternal age
Summary
The main strategies for the prevention of malaria during pregnancy in Nigeria are by chemoprophylaxis using sulphadoxine-pyrimethamine (SP) and use of long-lasting insecticide treated nets. In spite of the recommendation of two treatment doses of SP for intermittent preventive treatment of malaria during pregnancy[1], other antimalarial medicines such as CQ, pyrimethamine and proguanil are still used in many antenatal clinics. Mutations in specific genes of Plasmodium falciparum that confer resistance to antimalarial drugs are selected by sustained drug pressure [2]. Specific multiple point mutations in a gene make up a resistance marker for an antimalarial drug. The use of antimalarial drugs for prevention and treatment is a major strategy in the prevention of malaria in pregnancy. Sulphadoxine-pyrimethamine (SP) is currently recommended for intermittent preventive treatment of malaria during pregnancy in Nigeria, previously used drugs for prophylaxis such as chloroquine (CQ) and pyrimethamine are accessible as they are purchased over the counter. This study describes the markers of absence or presence of resistance to quinoline (Pfcrt and Pfmdr 1) and type 1 antifolate antimalarial medicines (Pfdhfr)
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have